Inovio Pharmaceuticals, Inc. (INO) Piper Sandler 37th Annual Healthcare Conference December 2, 2025 8:30 AM EST
Company Participants
Jacqueline Shea – CEO, President & Director
Michael Sumner – Chief Medical Officer
Conference Call Participants
Edward Tenthoff – Piper Sandler & Co., Research Division
Presentation
Edward Tenthoff
Piper Sandler & Co., Research Division
Good morning, everyone. My name is Ted Tenthoff. I’m a senior biotech analyst at Piper Sandler. And before I begin, I’m required to point out certain disclosures regarding the relationship between VIPER and our next presenting company, Inovio, which are posted both at the back of the room and also at the registration desk.
Inovio is awaiting BLA acceptance for INO-3107 for recurrent respiratory papillomatosis, which additionally, Inovio is developing a unique pipeline as well as in vivo protein production technology that I think is really, really interested and ultimately could dwarf even the opportunity in RRP.
Here with us today is Jacqueline Shea, PhD, President and CEO; and also Michael Sumner, Chief Medical Officer. Thanks both for joining us for making the trip up.
Jacqueline Shea
CEO, President & Director
Thanks for having us, Ted.
Question-and-Answer Session
Edward Tenthoff
Piper Sandler & Co., Research Division
So Jacqui, perhaps you can start out by describing recurrent respiratory papillomatosis. What do patients experience? And what is sort of the current standard of care — surgery and treatment?
Jacqueline Shea
CEO, President & Director
Yes. Great. So recurrent respiratory papillomatosis or RRP is a rare disease. So you may not have heard of it. It’s a serious nasty disease. And it’s caused by the human papilloma virus type 6 and 11. And what the virus does is it causes the growth of work-like growth in the airways.
What this means for patients is that it can be very difficult to talk
